Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26935-26945

  Ibarrola Villava, Maider ^a   Llorca Cardeñosa, Marta J ^a   Tarazona, Noelia ^a   Mongort, Cristina ^a   Fleitas, Tania ^a   Perez Fidalgo, José Alejandro ^a   Roselló, Susana ^a   Navarro, Samuel ^a   Ribas, Gloria ^a   Cervantes, Andrés ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Biomarkers; Gastric cancer; Gene expression; Immunohistochemistry; MicroRNA expression

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 124 3P; MICRORNA 128 3P; MICRORNA 130B 3P; MICRORNA 19A 3P; MICRORNA 223 3P; MICRORNA 34A 5P; PROTEIN ARID1A; PROTEIN CMET; PROTEIN PIK3CA; TUMOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; CADHERIN; CDH1 PROTEIN, HUMAN; CHROMATIN; MET PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARID1A GENE; ARTICLE; CDH1 GENE; CLINICAL FEATURE; CMET GENE; CONTROLLED STUDY; DOWN REGULATION; GASTRIC MUCOSA; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PIK3CA GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; TUMOR GENE; UPREGULATION; AGED; CHEMISTRY; CHROMATIN; FEMALE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH MUCOSA; STOMACH TUMOR;

AGED; BIOMARKERS, TUMOR; CADHERINS; CHROMATIN; EPIGENESIS, GENETIC; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84944474809     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4775     Document Type: Article

References (48)

1. Herrero R, Parsonnet J, Greenberg ER. 2014; Prevention of gastric cancer. JAMA. 312:1197-1198.
2. Cancer Genome Atlas Research Network. 2014; Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202-209.
3. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM. 2012; High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One. 7:e38892.
4. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, et al. 2013; Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 45:478-486.
5. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, et al. 2012; Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 44:570-574.
6. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ. 2010; MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 29:5761-5771.
7. Pan HW, Li SC, Tsai KW. 2013; MicroRNA dysregulation in gastric cancer. Curr Pharm Des. 19:1273-1284.
8. Azad N, Zahnow CA, Rudin CM, Baylin SB. 2013; The future of epigenetic therapy in solid tumors-lessons from the past. Nat Rev Clin Oncol. 10:256-266.
9. Esquela-Kerscher A, Slack FJ. 2006; Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259-269.
10. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. 2009; Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228-234.
11. Volinia S, Hiles I, Ormondroyd E, Nizetic D, Antonacci R, Rocchi M, Waterfield MD. 1994; Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics. 24:472-477.
12. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. 2005; Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:29.
13. Samuels Y, Velculescu VE. 2004; Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 3:1221-1224.
14. Vivanco I, Sawyers CL. 2002; The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489-501.
15. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, et al. 2013; Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 145:554-565.
16. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, et al. 2014; MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5:1837-1845.
17. Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A. 2014; Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci. 105:1032-1039.
18. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. 2000; A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 19:4947-4953.
19. Chen JD, Kearns S, Porter T, Richards FM, Maher ER, Teh BT. 2001; MET mutation and familial gastric cancer. J Med Genet. 38:E26.
20. Peters S, Adjei AA. 2012; MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 9:314-326.
21. Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, Ba MC, Lin SQ, Qi YC. 2010; Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol. 16:4986-4991.
22. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P. 2012; Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 12:50.
23. Firoozinia M, Zareian Jahromi M, Moghadamtousi SZ, Nikzad S, Abdul Kadir H. 2014; PIK3CA gene amplification and PI3K p110alpha protein expression in breast carcinoma. Int J Med Sci. 11:620-625.
24. Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H. 2013; PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol. 44:199-207.
25. Shinmura K, Kiyose S, Nagura K, Igarashi H, Inoue Y, Nakamura S, Maeda M, Baba M, Konno H, Sugimura H. 2014; TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer. J Surg Oncol. 109:189-197.
26. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. 2011; MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 20:1021-1027.
27. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. 2001; Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol. 40:638-643.
28. Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. 2012; Frequency of CDH1 germline mutations in gastric carcinoma coming from high-and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer. 12:8.
29. Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, Hsieh CB, Chen TW, Hsu HM. 2006; Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol. 12:2168-2173.
30. Cavallaro U, Christofori G. 2004; Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 4:118-132.
31. Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E, Torkamanzehi A. 2010; Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer. Arch Oral Biol. 55:809-814.
32. Starska K, Forma E, Lewy-Trenda I, Papiez P, Wos J, Brys M. 2013; Diagnostic impact of promoter methylation and E-cadherin gene and protein expression levels in laryngeal carcinoma. Contemp Oncol (Pozn). 17:263-271.
33. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, et al. 2012; Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 7:e40364.
34. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, et al. 2011; Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 33:100-103.
35. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF. 2014; ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol. 45:1258-1268.
36. Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK, Park DJ, Kim HH, Kang SB. 2014; Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies. Oncology. 88:234-240.
37. Abe H, Maeda D, Hino R, Otake Y, Isogai M, Ushiku AS, Matsusaka K, Kunita A, Ushiku T, Uozaki H, Tateishi Y, Hishima T, Iwasaki Y, et al. 2012; ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch. 461:367-377.
38. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C. 2009; MicroRNA profiling of human gastric cancer. Mol Med Rep. 2:963-970.
39. Wang QX, Zhu YQ, Zhang H, Xiao J. 2015; Altered MiRNA Expression in Gastric Cancer: a Systematic Review and Meta-Analysis. Cell Physiol Biochem. 35:933-944.
40. Shrestha S, Hsu SD, Huang WY, Huang HY, Chen W, Weng SL, Huang HD. 2014; A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 3:878-888.
41. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K, Baba H. 2012; Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 106:182-188.
42. Lu W, Xu Z, Zhang M, Zuo Y. 2014; MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. Int J Clin Exp Pathol. 7:7286-7296.
43. Xia J, Wu Z, Yu C, He W, Zheng H, He Y, Jian W, Chen L, Zhang L, Li W. 2012; miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 227:470-480.
44. Pierson J, Hostager B, Fan R, Vibhakar R. 2008; Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 90:1-7.
45. Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. 2013; Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107:505-510.
46. Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. 2013; Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 30:452.
47. Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X, Wang S, Wu X, Yang T, Huang F, Cai J, Zhu Q, Zhu W, et al. 2014; Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer. 110:1199-1210.
48. Livak KJ, Schmittgen TD. 2001; Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402-408.